Drug Profile

Elticertinib - Eli Lilly and Company

Alternative Names: PFL-721; ST-5924; STX-721

Latest Information Update: 08 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Scorpion Therapeutics
Developer Eli Lilly and Company
Class Antineoplastics; Small molecules
Mechanism of Action ErbB receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Non-small cell lung cancer

Most Recent Events

08 Jul 2026 Chemical structure information added
02 Jun 2026 Pharmacodynamics, pharmacokinetics, efficacy and adverse events data from the phase I/II trial in Non-small cell lung cancer presented at the 62^nd Annual Meeting of the American Society of Clinical Oncology 2026 (ASCO-2026)
16 Jun 2025 Elticertinib licensed to Pierre Fabre worldwide

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com